With the approval, QIAreach QFT will now be available to public health programs and institutions in more than 100 countries that qualify for Global Fund and/or UNITAID resources. It will also be available through the Stop TB Partnership's Global Drug Facility, Ellume said.

Ellume and Qiagen partnered to develop QIAreach QFT, which was launched in October and has also received the CE Mark.

Ellume issues recall of test for SARS-CoV-2 infection
Ellume is recalling its COVID-19 Home Test for detecting SARS-CoV-2 infection due to its potential to produce false-positive results, according to the...

FDA issues alert on Ellume at-home COVID-19 tests
Some home tests for COVID-19 manufactured by Ellume may deliver false-positive results due to a manufacturing issue, according to a safety communication...

FDA issues EUA for Ellume's at-home COVID-19 test
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for an over-the-counter at-home diagnostic test for COVID-19...

Qiagen releases portable SARS-CoV-2 antigen test
Qiagen has launched a portable, digital SARS-CoV-2 antigen test that can analyze more than 30 swab samples per hour. The company developed the QIAreach...